All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Anemia-related fatigue in myelodysplastic syndromes (MDS) can lead to dependance on red blood cell (RBC) transfusions and a reduced quality of life. Indeed, a retrospective multicenter study performed across France by the Francophone Myelodysplasia Group (Groupe Francophone des Myélodysplasies), analyzing 100 patients with MDS over a 6-month period, highlighted that 79% of patients had a high transfusion burden.1 Of these patients, 22% required inpatient hospitalization, with 36% of them requiring emergency RBC transfusion due to symptomatic anemia; the median total transfusion cost for each patient, during the 6-month period, was €16,188.1
At the European School of Haematology (ESH) 8th Translational Research Conference: Myelodysplastic Syndromes, Gregory A. Abel2 discussed the potential applications of a peri-transfusion quality-of-life assessment to help future transfusion decisions. He reported the workflow used to define the minimum hemoglobin level required in patients who undergo stem cell transplantation (SCT), as well as the overall feasibility of the assessment process.2 We summarize the findings below.
A panel of 13 expert physicians were brought together, which included 12 MDS experts and one transfusion medicine expert, to decide on the accepted hemoglobin threshold required to undergo RBC transfusion. A modified Delphi technique, incorporating elements from the RAND/UCLA Appropriateness Method, was used during multiple rounds of assessment, anonymous presentations of results, and discussions. The end goal was to reach a pre-specified consensus of 75%.
The study consisted of three rounds of assessments by the panel:
Results from the assessments are shown in Figure 1.
Figure 1. Hemoglobin level threshold for transfusion assessment accepted by the expert panel: A Round 1; B Round 2; C Round 3*
*Adapted from Abel2
The quality of life of patients was assessed 1 day before, and 7 days after RBC transfusion. All patients were required to be diagnosed with MDS, have a hemoglobin level ≥7.5 g/dL, and show no evidence of chronic heart failure or unstable angina. An assessment with +/− 5 points was considered potentially meaningful.
A total of 38 patients completed the full assessment. The changes in quality-of-life post-transfusion were as follows:
The mean increase between assessments was 14 points, while the mean decrease was 7 points. Patients who had a better baseline quality of life were found to have a greater overall increase. The number of RBCs in the 8-week follow-up was also higher in the assessed group compared to the historical control group (p = 0.03). A total of seven patients discussed their assessments with their providers, with three patients reporting that it affected their decision to pursue future transfusions.
A third of the patients experienced a measurable increase in quality of life 1 week after their transfusion. This highlights the potential for some patients to adopt a more limited transfusion schedule without compromising quality of life. Costs of care and hospitalization should ultimately be compared with costs of new treatments potentially able to avoid RBC transfusion dependence, and to reduce further clinical complications.
Factors predisposing failure to reach allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes
Lindholm et al. studied the proportion of patients failing to reach eligibility for HSCT and the factors predisposing...
Targeted sequencing of seven genes may improve classification of MDS
The National Myelodysplastic Syndromes (MDS) Natural History Study (NCT02775383) is a collaborative study involving the National Heart, Lung, and Blood Institute (NHLBI), National...
Subscribe to get the best content related to MDS delivered to your inbox